Royalty Pharma Announces Expansion of Leadership Team
Royalty Pharma has announced key changes to its leadership team, appointing Art McGivern as Executive Vice President, Investments & General Counsel, while promoting George Lloyd to Executive Vice President, Investments & Chief Legal Officer. McGivern joins from Goodwin Procter with extensive experience in transaction structuring in the life sciences sector. Lloyd, who has been with the company since 2011, will oversee the legal team as responsibilities increase due to the complexity of transactions. These changes aim to enhance Royalty Pharma's capacity to navigate its growing transaction pipeline.
- Art McGivern's extensive experience in transaction structuring is expected to strengthen Royalty Pharma's leadership and execution capabilities.
- The promotion of George Lloyd to Chief Legal Officer will ensure experienced oversight as the company faces increasing legal complexities.
- None.
- Art McGivern joins Royalty Pharma as EVP, Investments & General Counsel
- George Lloyd promoted to EVP, Investments & Chief Legal Officer
NEW YORK, Oct. 12, 2022 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced an expansion of its leadership team. Art McGivern has joined Royalty Pharma as Executive Vice President, Investments & General Counsel and George Lloyd has been promoted to Executive Vice President, Investments & Chief Legal Officer.
Pablo Legorreta, Royalty Pharma’s founder and Chief Executive Officer, commented, “We are thrilled that Art will join Royalty Pharma and strengthen our leadership team. Art brings decades of experience in transaction structuring across the life sciences innovation ecosystem. As Royalty Pharma has grown, so too have the demands on the legal team and Art's addition will expand our capacity to execute on our transaction pipeline. Furthermore, we are excited for George to become Chief Legal Officer and oversee our incredibly talented legal team as our responsibilities as a public company increase and our transactions become more complex.”
Art McGivern joins Royalty Pharma from Goodwin Procter where he was a partner in its Life Sciences Group. He has been Royalty Pharma’s lead outside lawyer on substantially all investment transactions since 2012. Art brings experience across public and private securities offerings, mergers and acquisitions, royalty-based financings and other complex transactions, and has advised companies in their ongoing corporate matters. Art has a BSCE from Tufts University and a JD from Boston University.
George Lloyd leads the legal and compliance functions at Royalty Pharma. He joined Royalty Pharma in 2011 after representing Royalty Pharma on all transactional work since 2006. George was previously a partner in Goodwin Procter’s Private Equity Group. He has an AB from Princeton University and a JD from New York University Law School.
About Royalty Pharma
Founded in 1996, Royalty Pharma is the largest buyer of biopharmaceutical royalties and a leading funder of innovation across the biopharmaceutical industry, collaborating with innovators from academic institutions, research hospitals and non-profits through small and mid-cap biotechnology companies to leading global pharmaceutical companies. Royalty Pharma has assembled a portfolio of royalties which entitles it to payments based directly on the top-line sales of many of the industry’s leading therapies. Royalty Pharma funds innovation in the biopharmaceutical industry both directly and indirectly - directly when it partners with companies to co-fund late-stage clinical trials and new product launches in exchange for future royalties, and indirectly when it acquires existing royalties from the original innovators. Royalty Pharma’s current portfolio includes royalties on more than 35 commercial products, including Vertex’s Trikafta, Kalydeco, Orkambi and Symdeko, Biogen’s Tysabri, AbbVie and Johnson & Johnson’s Imbruvica, Astellas and Pfizer’s Xtandi, GSK’s Trelegy, Novartis’ Promacta, Biohaven and Pfizer’s Nurtec ODT, Johnson & Johnson’s Tremfya, Roche’s Evrysdi, Gilead’s Trodelvy, and 12 development-stage product candidates.
Forward-Looking Statements
The information set forth herein does not purport to be complete or to contain all of the information you may desire. Statements contained herein are made as of the date of this document unless stated otherwise, and neither the delivery of this document at any time, nor any sale of securities, shall under any circumstances create an implication that the information contained herein is correct as of any time after such date or that information will be updated or revised to reflect information that subsequently becomes available or changes occurring after the date hereof. This document contains statements that constitute “forward-looking statements” as that term is defined in the United States Private Securities Litigation Reform Act of 1995, including statements that express the company’s opinions, expectations, beliefs, plans, objectives, assumptions or projections regarding future events or future results, in contrast with statements that reflect historical facts. Examples include discussion of Royalty Pharma’s strategies, financing plans, growth opportunities and market growth. In some cases, you can identify such forward-looking statements by terminology such as “anticipate,” “intend,” “believe,” “estimate,” “plan,” “seek,” “project,” “expect,” “may,” “will,” “would,” “could” or “should,” the negative of these terms or similar expressions. Forward-looking statements are based on management’s current beliefs and assumptions and on information currently available to the company. However, these forward-looking statements are not a guarantee of Royalty Pharma’s performance, and you should not place undue reliance on such statements. Forward-looking statements are subject to many risks, uncertainties and other variable circumstances, and other factors. Such risks and uncertainties may cause the statements to be inaccurate and readers are cautioned not to place undue reliance on such statements. Many of these risks are outside of Royalty Pharma’s control and could cause its actual results to differ materially from those it thought would occur. The forward-looking statements included in this document are made only as of the date hereof. Royalty Pharma does not undertake, and specifically declines, any obligation to update any such statements or to publicly announce the results of any revisions to any such statements to reflect future events or developments, except as required by law. Certain information contained in this document relates to or is based on studies, publications, surveys and other data obtained from third-party sources and Royalty Pharma’s own internal estimates and research. While Royalty Pharma believes these third-party sources to be reliable as of the date of this document, it has not independently verified, and makes no representation as to the adequacy, fairness, accuracy or completeness of, any information obtained from third-party sources. In addition, all of the market data included in this document involves a number of assumptions and limitations, and there can be no guarantee as to the accuracy or reliability of such assumptions. Finally, while the company believes its own internal research is reliable, such research has not been verified by any independent source. For further information, please reference Royalty Pharma’s reports and documents filed with the U.S. Securities and Exchange Commission (“SEC”) by visiting EDGAR on the SEC’s website at www.sec.gov.
Royalty Pharma Investor Relations and Communications
+1 (212) 883-6772
ir@royaltypharma.com
FAQ
What changes were announced in Royalty Pharma's leadership on October 12, 2022?
Who is Art McGivern and what experience does he bring to Royalty Pharma?
How will Art McGivern's appointment affect Royalty Pharma?
What role will George Lloyd assume in Royalty Pharma after his promotion?
